Nifekalant
Source: Wikipedia, the free encyclopedia.
Chemical compound
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Nifekalant (
INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia.[1]
It has the brand name Shinbit.
References
- PMID 11862758.
VGKCsTooltip Voltage-gated potassium channels
Blockers |
|
---|---|
Activators |
|
IRKsTooltip Inwardly rectifying potassium channel
Blockers |
|
---|---|
Activators |
|
Blockers |
|
---|---|
Activators |
K2PsTooltip Tandem pore domain potassium channel
Blockers |
|
---|---|
Activators |
VGSCsTooltip Voltage-gated sodium channels
Blockers |
|
---|---|
Activators |
|
Blockers | |
---|---|
Activators |
Blockers |
---|
CaCCsTooltip Calcium-activated chloride channel
Blockers |
|
---|---|
Activators |
Blockers | |
---|---|
Activators |
Blockers |
---|
TRPs Tooltip Transient receptor potential channels |
|
---|---|
LGICs Tooltip Ligand gated ion channels |
|
Channel blockers |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor agonists and antagonists |
| ||||||||||||
Na+/ K+-ATPase |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
cardiovascular system is a stub. You can help Wikipedia by expanding it. |